细胞周期蛋白依赖性激酶 (CDK) 4-6 抑制剂是激素阳性转移性乳腺癌 (MBC) 推荐的一线治疗选择。它们通过导致细胞周期停滞在 G1-S 期来发挥作用。中性粒细胞减少症是最常见的血液学副作用。在文献中，有关 CDK 4-6 抑制剂与大红细胞增多症之间关联的数据有限。我们旨在探讨大红细胞增多症对生存的影响。我们回顾性分析了 133 例在一线治疗中使用 CDK 4-6 抑制剂的新发激素阳性 MBC 患者。平均红细胞体积 (MCV) > 100 被认为是大红细胞症，患者被分为两组； MCV<100 和 MCV>100。对大红细胞增多症与临床病理特征、无进展生存期 (PFS) 和总生存期 (OS) 的关联进行了评估。42 名患者接受 palbociclib，81 名患者接受 ribociclib。中位 OS 确定为 33 个月，中位 PFS 确定为 22 个月。随访期间巨红细胞症发生率为 45.8%。第一个月有 4.2% 的患者出现大红细胞增多，第三个月有 16.7%，第六个月有 41.6%，第十二个月有 42.2%。单变量 Cox 回归分析结果发现，ER 受体水平、ki-67、6-12 个月时的大红细胞增多症和曾经的大红细胞增多症对 OS 有影响，并用多变量 Cox 回归模型进行了评估，观察到它们对 OS 有显着影响。 PFS 和 OS。巨红细胞增多症可能是预测接受 CDK 4-6 抑制剂的 MBC 患者 PFS 和 OS 的有用生物标志物。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

Cyclin Dependent Kinase (CDK) 4-6 inhibitors are the recommended first-line treatment option for hormone-positive metastatic breast cancer (MBC). They show their effects by causing cell cycle arrest in G1-S phase. Neutropenia is the most common haematological side effect. In the literature, data on the association between CDK 4-6 inhibitors and macrocytosis are limited. We aimed to investigate the effect of macrocytosis on survival.We retrospectively analysed 133 patients with de novo hormone positive MBC using CDK 4-6 inhibitors in first line treatment. Mean Corpuscular Volume (MCV) > 100 was considered macrocytosis and patients were divided into two groups; MCV<100 and MCV >100. The association of macrocytosis with clinicopathological features, Progression Free Survival (PFS) and Overall Survival (OS) were evaluated.42 patients were receiving palbociclib and 81 patients were receiving ribociclib. Median OS was determined as 33 months and median PFS was determined as 22 months. Macrocytosis ever rate was 45.8 % during follow-up. Macrocytosis was observed in 4.2 % of the patients in the first month, 16.7 % in the third month, 41.6 % in the sixth month and 42.2 % in the twelfth month. ER receptor level, ki-67, macrocytosis at 6-12 months and macrocytosis-ever which were found to affect OS as a result of univariate Cox regression analysis, were evaluated with multivariate Cox regression models and it was observed that they had significant effect on PFS and OS.Macrocytosis may be a useful biomarker for the prediction of PFS and OS in MBC patients receiving CDK 4-6 inhibitors.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.